AI assistant
Celyad Oncology SA — Share Issue/Capital Change 2015
May 13, 2015
3927_mrq_2015-05-13_c7e1df99-0971-42f8-a83f-88d8bdf01a24.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Information on the total number of voting rights and shares (Article 15 of the Law of 2 May 2007)
Celyad SA (NYSE Euronext Brussels and NYSE Euronext Paris: CYAD), discloses the information required under article 15, § 1 of the Law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.
Following the exercise of 500 warrants of the Company on 11 May 2015, the share capital is increased to 27,440,130.63 EUR and is represented by 7,847,687 shares.
FIGURES – MODIFIED ON 11 MAY 2015 FOLLOWING THE EXERCISE OF WARRANTS
New shares issued following the exercise of Company's warrants: 500
Company's share capital: 27,440,130.63 EUR
Total number of shares with voting rights: 7,847,687
Total number of voting rights (= denominator): 7,847,687
STATUTORY THRESHOLDS - UNCHANGED
Statutory thresholds for participation (article 12 of the by-laws): 5%, 10%, 15 %, 20% and so by increments of 5 %.
CONTACT PERSON FOR REGULATED INFORMANTION (FINANCIAL, TRANSPARENCY)
According to Law, any transparency declaration must be sent to our Company by email to the attention of Patrick Jeanmart, Chief Financial Officer (CFO) : [email protected]
Further questions about the content of this release can be sent to [email protected].
***END***
For more information, please contact:
For Europe : Consilium Strategic Communications
Amber Bielecka, Chris Welsh, and Laura Thornton - T: +44 (0)20 3709 5700 – [email protected]
For the U.S. : The Ruth Group
Lee Roth (Investors), and Kirsten Thomas (Media) - T: +1 646 536 7012 / 7014 - [email protected]
For France : NewCap Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 - [email protected]
Celyad
Christian Homsy, CEO and Julie Grade, Corporate Communications Manager : T: +32 (0)10 39 41 00 [email protected]
To subscribe to Celyad's newsletter, visit www.celyad.com
Follow us on Twitter @CelyadSA
About Celyad
Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrolment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.
Celyad's shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD.
To learn more about Celyad, please visit www.celyad.com.
Forward looking statements
In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cathez, OnCyte, Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, C-Cathez, CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the company.